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Background : Diuretic resistance is a common problem issue in acute decompensation of advanced heart failure
Objective : In this review, we will discuss how to diagnose the advanced heart failure and the underlying 
mechanism of diuretic resistance in heart failure patients. We also describe pharmacologicalvand non-pharmaco-
logical strategies to overcome this issue.
Discussion : Advanced heart failure (HF) is used to characterize  patients in HF with severe symptoms, recurrent 
decompensation and severe cardiac dysfunction.  Most of HF hospitalization are due to signs and symptoms of 
fluidcoverload. Recurrent congestionccould worsen patients outcomes. Loop diuretics are recommended for 
thectreatmentcofkcongestionqinprHF patient. However,ndiuretic resistance is a common problem issue in acute 
decompensation of advanced chronic heart failure (ACHF) patients and established prognostic factor. The 
pathophysiology of diuretic resistance is very complex, and several etiologies mayabe involved. It derives from 
multiple factors, including reduced delivery of the diuretic to its luminal site of action, neurohormonal activation, 
tubular compensatory adaptation, and drug interactions
Conclusion : Diuretic resistance has emerged as an independent factor behind worse HF patient outcomes, namely 
in-hospital worsening, early post-discharge mortality, and rehospitalizations. Once the diuretic resistance has 







 Heart failure (HF) is a clinical syndromes that is character-
ized by typical symptoms such as breathlessness, ankle swelling, and 
fatigue. Signs may be accompannied by consisted of elevated jugular 
venouss pressures (JVP), pulmonary crackles, and peripheral edema 
which can cause a structural and/or functional cardiac abnormality, 
resulting in reduced cardiac output and/or elevated intracardiac 
pressures at rest or during stress. Advanced HF is used to characterize 
patients with severe symptoms, recurrent decompensation, and severe 
cardiac dysfunction problem.1
 The prevalence of HF is approximately 1-2% of the adult 
population in developed countries and increase more than 10% among 
people >70 years of age, whereas estimated the prevalence of patients 
with advanced heart failure is about 1% until 10% of the overall heart  
failure population. It was predicted to increase because of the growing  
number of patients with heart failure and their better treatment and 
survival rate.2
 Most of the HF hospitalizations are due to signs and 
symptoms of fluid overload. Recurrent congestion could worsen 
patients outcomes. Loop diuretics are recommended for the treatment 
of congestion in heart failure patient. Diuretic therapy is mainly 
described in the curren guidelines for HF treatment. However, diuretic 
resistance is a common problem issue in acute decompensation of 
advance chronic heart failure (ACHF) patients and established prognos-
tic factor. Some early report estimated the prevalence of diuretic 
resistance about 20 %-30% in HF patients population.3
 In this review, we will discuss how to diagnose the advance 
heart failure and the underlying mechanism of diuretic resistance in HF 
patients. We also describe pharmacological and non-pharmacological 
strategies to overcome this issue.
2. Discussion
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2.2.1 Definition of Advanced Heart Failure
 The definition of advanced HF is evolved time by time to 
have better comprehension directing clinicians to diagnose. On ESC 
2007, advanced HF emphasizes patients who remain severely 
symptomatic despite optimal guideline-directed management regard-
less ofoleft ventricular ejection fraction (LVEF), including patients with 
advanced HF who remain ambulatory but are essentially New York 
Heart Association (NYHA) class IV. In other references, simplified 
advanced HF by patients characterized severe symptoms, recurrent 
decompensation, and severe  cardiac dysfunction.4
 In 2018, ESC updated the definition of advanced HF with 
four categories. For the first, severe and persistent symptoms of heart 
failure (NYHA class III (advanced) or IV). Second, severe cardiac 
dysfunction defined by a reduced LVEF ≤30%, isolated RV failure (e.g., 
ARVC) or non-operable severe valve abnormalities or congenital abnor-
malities or persistently high (or increasing) BNP or NT-proBNP values 
and data of severe diastolic dysfunction or LV structural abnormalities 
according to the ESC definition of the HFpEF and HfmrEF.5 Then for 
Third, episodes of pulmonary or systemic congestion requiring 
high-dose intravenous diuretics (or diuretic combinations), episodes of 
low output requiring inotropes or vasoactive drugs or malignant 
arrhythmias causing more than 1 unplanned visit or hospitalization in 
the last 12 months. Furthermore, the fourth severe impairment of 
exercise capacity with the inability to exercise or low 6MWTD (<300 
m) or pVO2 (<12 – 14 mL/kg/min), estimated to be ofhcardiac origin.6
2.2.2 Detecting Congestion in Heart Failure
 Congestion in HF can be defined as signs and symptoms of 
extracellular fluid accumulation that result in increased cardiac filling 
pressures. Filling pressures are the integrated result of the cardiac 
systolic and diastolic function, plasma volume, and venous capaci-
tance/compliance. HF with increased neurohumoral activation induces 
a state of increased renal sodium and water avidity resulting in an 
increased plasma volume. Also, increased sympathetic output leads to 
splanchnic arterial and venous constriction resulting in blood redistri-
bution from the splanchnic capacitance vasculature to the circulatory 
volume. This increases the adequate circulating volume by redistribu-
tion, in a state where volume expansion is  already present.7
 Physical signs and symptoms of congestion are based on 
detecting increased filling pressures   and/or the extravascular fluid 
build-up secondary to the increased filling pressures. As such, the 
jugular venous pressure (JVP) is the most useful physical finding for 
determining a patient's volume status. Not only does a JVP detect 
systemic congestion, but there is good sensitivity (70%) and specificity 
(79%) between high JVP and elevated left-sided filling pressure.   
Changes in   JVP with   therapy   usually   parallel changes in   left- sided 
filling pressure, although significant inter-observer variability regard-
ing the extent of JVP elevation exists. Also, while a chest X-ray can 
show signs ofllung congestion and pleural fluid, 20% of patients with 
congestion exhibit a normal chest X-ray.8
 In comparison to chest X-ray, lung ultrasound is better in 
ruling out interstitial edema and pleural effusions. Lung ultrasound 
detects B-lines originating from an extravasated fluid into the intersti-
tium and alveoli. More than three B-lines in more than two intercostal 
spaces bilaterally are considered diagnostic for the detection of intersti-
tial and alveolar edema in acute heart  failure.9
 Echocardiographic parameters can be used to estimate right 
and left-sided filling pressures, although with less certainty in acute 
heart failure. Estimation of right atrial pressures can be performed by 
assessing the collapsibility and width of the vena cava. Doppler imaging 
and tissue Doppler can be used to assess left-sided filling pressures. 
With rising filling pressures, an increase in early diastolic mitral inflow 
velocities (E wave) occurs.10 This is indicative of increased filling 
pressures in the presence ofaa low e', especially if E-wave deceleration 
time is short and A-wave velocities are low. Nevertheless, the use of e' 
might be limited in advanced heart failure. Guidelines suggest the 
measurement ofanatriuretic peptides (NPs) in all patients with acute 
heart failure, especially to distinguish from non-cardiac causes ofsdys-
pnoea (class I recommendation, level ofpevidence A). NPs have a high 
negative predictive value for ruling out acute heart failure with conges-
tion [thresholds for excluding acute heart failure; B-type natriuretic 
peptide (BNP) <100pg/mL, N-terminal pro BNP (NT-proBNP) < 300 
ng/mL and mid-regional pro atrial natriuretic peptide <120   pg/mL]. 
In patients with a history of heart failure or cardiac disease, the combi-
nation of signs and symptoms ofocongestion, indicative chest X-ray and 
the measurement of elevated NPs allows for the diagnosis of conges-
tion.11
2.3 Mechanism of Action of Diuretics in Heart Failure
2.3.1 Physiology Diuresis in Kidney
 As blood flows through the kidney, it passes into glomerular 
capillaries located within the cortex (outer zone of the kidney). These 
glomerular capillaries are highly permeable to water and electrolytes. 
Glomerular capillary hydrostatic pressure drives (filters) water and 
electrolytes into Bowman's space and into the proximal convoluting 
tubule (PCT). About 20% of the plasma that enters the glomerular 
capillaries is filtered (termed filtration fraction). The PCT, which lies 
within the cortex, is the site of sodium, water, and bicarbonate 
transport from the filtrate (urine), across the tubule wall, and into the 
interstitium of the cortex. About 65-70% ofsthe filtered sodium is 
removed from the urine found within the PCT (this is termed sodium 
reabsorption).12 This sodium is reabsorbed isosmotically, meaning that 
every molecule of sodium that is reabsorbed is accompanied by a 
molecule of water. As the tubule dives into the medulla or middle zone 
of the kidney, the tubule becomes narrower and forms a loop (Loop of 
Henle) that reenters the cortex as the thick ascending limb (TAL) that 
travels back to near the glomerulus. Because the interstitium of the 
medulla is very hyperosmotic and the Loop of Henle is permeable to 
water, water is reabsorbed from the Loop of Henle and into the medul-
lary interstitium. This loss of water concentrates the urine within the 
Loop of Henle.13
 The TAL, which is impermeable to water, has a cotransport 
system that reabsorbs sodium, potassium, and chloride at a ratio of 
1:1:2. Approximately 25% of the sodium load of the original filtrate is 
reabsorbed at the TAL. From the TAL, the urine flows into the distal 
convoluting tubule (DCT), which is another site of sodium transport 
(~5% via a sodium- chloride cotransporter) into the cortical intersti-
tium (the DCT is also impermeable to water). Finally, the tubule dives 
back into the medulla as the collecting duct and then into the renal 
pelvis, where it joins with other collecting ducts to exit the kidney as 
the ureter. The distal segment of the DCT and the upper collecting duct 
has a transporter that reabsorbs sodium (about 1-2% of filtered load) in 
exchange for potassium and hydrogen ion, which are excreted into the 
urine14. It is important to note two things about this transporter. First, 
its activity is dependent on the tubular concentration of sodium so that 
when sodium is high, more sodium is reabsorbed, and more potassium 
and hydrogen ion are excreted. Second, this transporter is regulated by 
aldosterone, which is a mineralocorticoid hormone secreted by the 
adrenal cortex. Increased aldosterone stimulates the reabsorption of 
sodium, which also increases the loss of potassium and hydrogen ion to 
the urine. Finally, water is reabsorbed in the collected duct through 
special pores that are regulated by antidiuretic hormone, which is 
released by the posterior pituitary. ADH increases the permeability of 
the collecting duct to water, which leads to increased water reabsorp.
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tion, more concentrated urine, and reduced urine outflow (antidiure-
sis). Nearly all of the sodium originally filtered is reabsorbed by the 
kidney, so that less than 1% of originally filtered sodium remains in the 
final  urine.15
2.3.2 Mechanism of Diuretic Drugs
 Diuretic drugs will increase urine output by the kidney. This 
is accomplished by altering how the kidney handles sodium. If the 
kidney excretes more sodium, then water excretion will also increase. 
Most diuretics produce diuresis by inhibiting the reabsorption of 
sodium at different segments of the renal tubular system. Sometimes a 
combination of two diuretics is given because this can be significantly 
more effective than either compound alone (synergistic effect). The 
reason for this is that one nephron segment can compensate for altered 
sodium reabsorption at another nephron segment; therefore, blocking 
multiple nephron sites significantly enhances efficacy.16
• Loop Diuretics
 Loop diuretic action by inhibit the sodium-potassium-chlo-
ride cotransporter in the thick ascending limb. This transporter normal-
ly reabsorbs about 25% of the sodium load; therefore, inhibition of this 
pump can lead to a significant increase in the distal tubular concentra-
tion of sodium, reduced hypertonicity of the surrounding interstitium, 
and less water reabsorption in the collecting duct. This altered handling 
of sodium and water leads to both diuresis (increased water loss) and 
natriuresis (increased sodium loss). By acting on the thick ascending 
limb, which handles a significant fraction of sodium reabsorption, loop 
diuretics are very powerful diuretics. These drugs also induce renal 
synthesis of prostaglandins, which contributes to their renal action, 
including the increase in renal blood flow and redistribution of renal 
cortical blood flow.17
• Thiazide Diuretics
 Thiazide diuretics, which are the most commonly used 
diuretic, inhibit the sodium- chloride transporter in the distal tubule. 
Because this transporter normally only reabsorbs about 5% of filtered 
sodium, these diuretic are less efficacious than loop diuretics in produc-
ing diuresis and natriuresis. Nevertheless, they are sufficiently powerful 
to satisfy many therapeutic needs requiring a diuretic. Their mecha-
nism depends on renal prostaglandin production.6
 Because loop and thiazide diuretics increase sodium delivery 
to the distal segment of the distal tubule, this increases potassium loss 
(potentially causing hypokalemia) because the increase in distal 
tubular sodium concentration stimulates the aldosterone-sensitive 
sodium pump to increase sodium reabsorption in exchange for potassi-
um and hydrogen ion, which are lost to the urine. The increased hydro-
gen ion loss can lead to metabolic alkalosis. Part of the loss of potassi-
um and hydrogen ion by loop and   thiazide diuretics results   from   
activation ofathe RAA system that occurs because of reduced blood 
volume and arterial pressure. Increased aldosterone stimulates sodium 
reabsorption and increases potassium and hydrogen ion excretion into 
the urine.18
• Potassium-sparing Diuretics
 There is a third class of diuretic that is referred to as potassi-
um-sparing diuretics. Unlike loop and thiazide diuretics, some of these 
drugs do not act directly on sodium transport. Some drugs in this class 
antagonize   the actions   of aldosterone (aldosterone receptor antago-
nists) at the distal segment of the distal tubule. This causes more 
sodium (and water) to pass into the collecting duct and be excreted in 
the urine.18 They are called K+-sparing diuretics because they do not 
produce hypokalemia like the loop and thiazide diuretics. The reason 
for this is that by inhibiting aldosterone-sensitive sodium reabsorption, 
less potassium and hydrogen ion are exchanged for sodium by this 
transporter, and therefore less potassium and hydrogen are lost to the 
urine. Other potassium-sparing diuretics directly inhibit sodium 
channels associated with the aldosterone- sensitive sodium pump and it   
have similar effects on potassium and hydrogen ion as the aldosterone 
antagonists. Their mechanism depends on renal prostaglandin produc-
tion. Because this class of diuretic has relatively weak effects on overall 
sodium balance, they are often used in conjunction with thiazide or 
loop diuretics to help prevent hypokalemia.19
• Carbonic Anhydrase Inhibitors
 Carbonic anhydrase inhibitors inhibit the transport of     
bicarbonate out of the proximal convoluted tubule into the interstitium, 
which leads to less sodium reabsorption at this site and, therefore, 
greater sodium, bicarbonate and water loss in the urine. These are the 
weakest of the diuretics and seldom used in cardiovascular disease. 
Their main use is in the treatment of glaucoma.20
2.4 Diuretic Resistance 
 The general definition refers to the failure to achieve 
effective congestion relief despite appropriate or escalating doses of 
diuretics. It can be defined by inadequate response to diuretic therapy 
(e.g., failure to lose 0.5-1kg of weight per day) when the following 
measures are ensured: the absence of third space overload with 
intravascular volume depletion, dietary salt restriction (fractional 
excretion of sodium <2%) and discontinuation of nonsteroidal anti-in-
flammatory drugs. Some early reports estimated the prevalence of 
diuretic resistance to be 20%-30% among HF patients. However, the 
lack of a formal definition makes it impossible to properly assess the 
numbers.1
2.4.1 Pathophysiology of Diuretic Resistance
` The pathophysiology of diuretic resistance is very complex, 
and several etiologies may be involved. It derives from multiple factors, 
including reduced delivery of the diuretic to its luminal site of action, 
neurohormonal activation, tubular compensatory adaptation, and drug 
interactions.6
• Reduced Delivery of the Diuretic to its site of Action
 Reduced delivery of the diuretic to its site of action is closely 
related to its decreased bioavailability. In HF patients, increased 
peripheral and bowel wall edema leads to reduced absorption of the 
diuretic, with a more marked effect when oral furosemide is used.1
 HF itself, as well as concurrent chronic kidney disease (CKD) 
(urate and other competing organic acids), may lead to decreased 
glomerular filtration rate, which in turn leads to impaired secretion of 
diuretics by the organic acid transporter into the proximal tubule. 
Reduced glomerular filtration rate can, therefore, reduce delivery or 
reduce the active secretion of loop diuretics into their site ofaaction. 
Moreover, CKD has been proposed as a contributing factor to the 
development of HF overall, regardless of left ventricular ejection 
fraction. CKD leads to volume retention, altered calcium-phosphate 
metabolism, hyperparathyroidism, vitamin D deficiency, anemia, and 
the accumulation of uremic toxins.3
 Renal dysfunction caused by intra-abdominal hypertension 
and cardiorenal syndromes is also a plausible mechanism ofadiuretic 
resistance through venous congestion. Intra-abdominal hypertension 
reliefyimproves renal perfusion, renal filtration, and diuresis. It is 
usually present in up to 60% of acutely decompensated HF patients. It 
is very important to emphasize the need to detect third-space overload 
10
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as opposed to intravascular overload because both the kidneys and 
diuretic therapy can only act in vascular overload.4
 Persistent diuretic use in patients who are already suffering 
from intravascular volume depletion further activates the renin-angio-
tensin-aldosterone (RAA) axis and makes diuretic resistance dependent   
on   renal blood flow. Sodium and chloride measurements may indicate 
when the vascular volume has been optimized because they decrease as 
euvolemia approaches. These may serve as more reliable markers 
ofadecongestion as opposed to the clinical signs and symptoms 
traditionally used to guide decongestive therapy.7 Clinical signs and     
symptoms lack sensitivity and specificity but do raise the need for 
further clinical evaluation. Natriuretic peptides are helpful for diagno-
sis and prognosis but lack the power to properly monitor volume status. 
Newer approaches point to quantitative blood volume analysis as a 
means to differentiate hypervolemia profiles. Appropriate profiling of 
volume overload in HF, according to blood volume, has therapeutic 
implications and may aid patients with diuretic resistance, redirecting 
them to other forms of decongestion.4
 Another mechanism ofgdiuretic activity impairment involves 
increased reabsorption of sodium and chloride in the proximal tubule, 
leading to decreased delivery of these substrates to the distal areas of 
the nephron where loop diuretics act. This mechanism causes diuretic 
resistance through decreased substrate availability to the sodium- 
potassium-chloride cotransport system.9
 Albumin levels also correlate to diuretic action because they 
are high-affinity albumin- binding molecules more than 90%. Hypoal-
buminemia increases the drug distribution volume and prevents 
suitable kidney delivery. On the other hand, high levels of albuminuria 
decrease loop diuretic delivery. Increased urine albumin binds to 
diuretics, preventing their ligation to the sodium-potassium-chloride 
receptors and thus impairing their action.20
• Neurohormonal Activation
 Neurohormonal activation is strongly related to RAA axis 
upregulation. Loop diuretics can activate the RAA axis through a 
variety of mechanisms. They induce renin secretion through the direct 
blockade of the macula densa sodium-potassium-chloride cotransport 
system, thus leading to increased renin and aldosterone in a volume-in-
dependent pathway. Furthermore, diuretics induce renal prostacyclin 
production, which increases renin secretion. Finally, diuretics induce
volume contraction, thus activating renin secretion through vascular 
stimulation. RAA axis activation eventually leads to increased sodium 
reabsorption, prompting the onset of post-diuretic sodium retention 
and the braking phenomenon.21
 Post-diuretic sodium retention is one of the processes 
through which diuretic resistance may be established, and it arises as 
soon as the concentration of diuretic in the tubular fluid drops below 
the therapeutic threshold. A negative net sodium balance in the 24 
hours between natriuresis and post-diuretic sodium retention may not 
be achieved in the event of dietary non-compliance, rendering the 
diuretic effect insignificant. The braking phenomenon, on the other 
hand, is defined as the decrease in diuresis volume after multiple 
same-dose administrations of diuretic. This is linked to RAA axis activa-
tion and compensatory changes in the nephron.9
• Tubular Compensatory Readaptation
 Tubular readaptation is another mechanism that helps 
explain the reduced diuretic response. Owing to the above-mentioned 
activation of the RAA axis, as well as the braking phenomenon, 
proximal tubular reabsorption arises, leading to increased sodium 
uptake in this area of the nephron. Simultaneously, the chronic use 
ofdloop diuretics, which inhibit sodium uptake in the loop of Henle, 
leads to increased sodium delivery to the distal tubular system, 
resulting in compensatory hyperplasia and hypertrophy. This means 
that the patient would retain more sodium and thus water than a 
diuretic-naïve patient. This resistance mechanism can be overcome 
using a sequential nephron blockade with thiazide diuretics.4
• Drug Interactions
 Some drugs, such as nonsteroidal anti-inflammatory drugs 
(NSAIDs), can reduce the effect of diuretics. NSAIDs may cause diuretic 
resistance in a number ofaways, particularly decreased prostaglandin 
synthesis, decreased renal vasodilation, increased renal reabsorption in 
areas of the nephron other than the loop of Henle and hypertension.9
 Evidence regarding the effect of low-dose aspirin (<1 
mg/kg/day) on a diuretic response, in particular, is more scarce and 
controversial. A previous study reported that chronic low-dose aspirin 
could profoundly affect platelet prostaglandin production without 
affecting diuretic-stimulated renal prostacyclin production or plasma 
renin activity. However, Jhund et al. demonstrated that the dilatation
Figure 1. Sites and Mode of Action and Effects on Sodium Reabsorption in the Nephron of Different Diuretics
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on vena could occur following furosemide administration could be 
inhibited by both high and low dose-aspirin. Furthermore, Hall noted 
an important reduction in the need for diuretics when daily aspirin 
administration was stopped. There is also some evidence that aspirin, 
even at a low dose, may neutralize the favorable effects of angiotensin-
2.4.2 Management for Diuretic Resistance 
• Salt Restriction
 Dietary sodium restriction is a key determinant of diuretic 
efficacy. When dietary sodium intake is high, post-diuretic sodium 
retention compensates almost entirely for the loop- diuretic-induced 
sodium loss. Conversely, if sodium intake is restricted, post-diuretic 
sodium retention is minimized, resulting in a negative fluid and sodium 
balance. Thus, restricting sodium intake to less than 100 mEq/day 
mitigates the effect of post-diuretic sodium retention and helps achieve 
a negative sodium balance. A 24-hour urinary sodium excretion of more 
than 100 mEq/day or fractional excretion of sodium value >2% 
indicates non-compliance with sodium restriction and  rules out true 
diuretic  resistance.9
• Discontinue concomitant use of nonsteroidal anti-inflammatory drugs
 Concomitant use of NSAIDs is a major cause of diuretic 
failure, and discontinuing them can significantly improve diuretic  
effectiveness.9
• Establish the Effective Single Dose
 Diuretics have a dose-response   curve,    and    the effect only    
begins once the diuretic level reaches a therapeutic threshold within the 
converting enzyme inhibitors by blocking prostaglandin production and 
enhancing the vasoconstrictor potential of endothelin. In patients with 
HF, aspirin should be avoided wherever possible, and other antithrom-
botic agents that respect the integrity of prostaglandin metabolism 
should be considered22.
renal tubular lumen. In conditions such as CKD and cardiorenal 
syndrome, the dose-response curve shifts downwards and towards the 
right. This means that these patients need higherjdoses of loop diuretics 
to achieve the therapeutic drug level at the site of action. Diuretic doses 
below said threshold are ineffective, so a higher effective single loop 
diuretic dose is needed rather than administering an inadequate dose 
more frequently.4
• Increase the dose frequency of loop diuretics
 Because most loop diuretics are short-acting, increasing the 
dose frequency can help overcome post-diuretic sodium retention and 
restore  diuretic response.4
• Diuretic Substitution
 Gastrointestinal absorption and the bioavailability ofbdiffer-
ent diuretics belonging to the same class can vary considerably, and this 
could be a factor behind a poor response. Furosemide has a bioavail-
ability of about 50%, whereas torsemide and bumetanide have almost 
completed absorption (80-100%). At times, replacing furosemide with 




Figure 2. Mechanism of Diuretic Resistance in Heart Failure.11 
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 Sometimes, administering diuretics intravenously instead of 
orally is all that is needed to improve diuresis. Oral absorption may be 
altered in the presence of gastrointestinal edema, gastroparesis, and   
delayed gastric emptying. Drug concentration at the site of diuretic   
action in the tubule lumen may be inadequate due to decompensated 
HF, renal hypoperfusion, or impaired secretion as a result of hypoalbu-
minemia.23
 Compared to bolus doses, continuous diuretic infusion may 
be more effective in improving diuresis. It may decrease fluctuations in 
intravascular volume, resulting in a more gradual and relatively 
constant hourly urine output and limiting the effect of post-diuretic 
sodium retention. Some studies found that furosemide administered as 
a continuous infusion was more effective than intermittent bolus doses 
since significantly less furosemide was required to produce the same 
diuresis and due to the elimination of a diuretic-free interval (during 
which compensatory sodium retention occurs).5 In the Diuretic Optimi-
zation Strategies Evaluation (DOSE) trial, there were no significant 
differences in patients' global symptom assessment or in the change in 
renal function between the two strategies.24
• Sequential Nephron Blockade
 A sequential sodium uptake blockade in different nephron 
segment by means of a combination of two or more diuretics from 
different classes may produce an additive or synergistic mechanism of 
action and diuretic response and can be an effective approach in 
resistant cases.14
 
• Management of intraabdominal pressure
 Intra-abdominal hypertension is defined as a sustained 
intra-abdominal pressure of 12 mmHg or above. Splanchnic and 
interstitial congestion may cause elevated intra-abdominal pressure in 
the absence of ascites in acute decompensated HF. In such patients, a 
rise in intra- abdominal pressure increases renal venous pressure, 
thereby reducing the transanal perfusion gradient and renal perfusion. 
Elevated intra-abdominal pressure also causes increased renal intersti-
tial pressure that opposes net filtration pressure. Both contribute to 
renal impairment and diuretic resistance.9 When intravenous loop 
diuretic therapy fails, measuring intra-abdominal pressure is an 
inexpensive and minimally invasive procedure that rules out a diuretic 
resistance cause. If intra-abdominal hypertension or abdominal 
compartment syndrome (defined as a sustained intra-abdominal 
pressure of >20 mmHg, which is associated with new organ dysfunc-
tion) is identified, a reduction in intra-abdominal pressure by mobiliz-
ing third-space fluid can be achieved through a combination of diuret-
ics, vasodilators and/or inotropes. Abundant ascites can be managed 
with paracentesis, ultrasound, or computer tomography guidance if 
needed. In certain patients, ultrafiltration (UF) may be appropriate. The 
therapeutic aim is to achieve an abdominal perfusion pressure (calcu-
lated as the mean arterial pressure minus the intra-abdominal pressure) 
of over 60 mmHg (with an intra-abdominal pressure of 5 to 7 mmHg), 
which signifies a favorable outcome (improvement in renal perfusion, 
renal filtration, and diuresis).24
• Infusion with Albumin
 Simultaneous infusion    of    a    diuretic and    albumin could    
slightly improve diuretic resistance. A meta-analysis of eight random-
ized clinical trials of adults with hypoalbuminemia, comparing the 
co-administration of loop diuretics and albumin versus loop diuretics 
alone, found transient effects of modest clinical significance with the 
former strategy. However, this intervention should only be considered 
in severely hypoalbuminemia patients when the approaches discussed 
above have failed.23
• Renal Dose Dopamine
 Low doses ofLdopamine (<3 mcg/kg/min) selectively work 
on peripheral dopaminergic receptors resulting in vasodilation in the 
renal, coronary, splanchnic, and cerebral circulations. Two recent trials 
of dopamine in acute HF - the Dopamine in Acute Decompensated 
Heart Failure II (DAD-HF II) trial and the Renal Optimization Strategies 
Evaluation (ROSE) trial - have shown no added benefit with the 
addition of dopamine to standard therapy with high-dose diuretics. 
Thus, on the basis of current data, dopamine has no role in nonhypoten-
sive patients with acute HF.24
• Alternative Pharmacological Therapies
 Hypertonic saline works osmotically to pull free water from   
the   interstitial fluid into the renal vasculature. In addition, to increase 
renal blood flow, it improves sodium delivery to the loop of Henle, thus 
restoring some of the loop diuretics' effect. Several studies have report-
ed better diuresis, improved renal function and shorter hospital stay 
when hypertonic saline is added to  loop diuretic therapy.4
 Glucocorticoids may promote diuresis and protect renal 
function in patients with acute HF. Liu et al. reported the effects of 
prednisolone in 13 congestive HF patients with significant volume 
overload and diuretic resistance who had failed to respond to a conven-
tional sequential nephron blockade treatment strategy. They reported 
an improvement in diuresis, clinical status, and renal  function.25
 Levosimendan was studied in patients presenting with acute 
HF in the Randomized Multicenter Evaluation of Intravenous Levosim-
endan Efficacy (REVIVE) studies. These showed that levosimendan 
improved renal function and diuretic response in such patients. Howev-
er, there was also an increased risk of arrhythmia and hypotension.22
 Nesiritide is a synthetic B-type natriuretic peptide (BNP) 
approved by the Food and Drug Administration for symptomatic relief 
due to   its favorable   effects   on hemodynamics, dyspnea, and renal 
function. However, both the ROSE trial and ter Maaten et al. (2015) 
found no additive effect of using low-dose nesiritide added to diuretic 
therapy in terms of decongestion or improved   renal function. Experi-
mental research has shown that renal delivery of BNP had significantly 
greater beneficial effects than systemic delivery. It could be that a 
higher systemic dose is needed; however, the usage there of would 
increase the incidence of adverse effects  such as hypotension.26
 Vasopressin-2-receptor antagonists may promote aquaresis 
by blocking the effects of vasopressin on the vasopressin-2-receptors 
located in the collecting ducts, thus blocking the reabsorption of free 
water. This promotes water clearance without affecting sodium 
Table 1.Combination diuretic therapy25
To an effective or maximal safe dose of a loop diuretic add: 
Distal convuluted tubule diuretics
 Metolazone 2.5-10 mg per os daily (duration or frequency
 adjusted based on the target weight)
 Hydrochlorothiazide (or equivalent) 25-100mg os daily
 Chlorothiazide 500-1000 mg intrvenously
Proximal tubule diuretics
 Acetazolamide 250-375 mg daily or up to 500 mg intravenously
Potassium-sparing diuretics
 Spironolactone 100-200 mg daily
 Amiloride 5-10 mg daily
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balance. In the Efficacy of Vasopressin Antagonism in Heart Failure 
Outcome Study with Tolvaptan (EVEREST) trial, tolvaptan at a dose of 
30 mg once daily for a minimum of 60 days had no effect on total 
mortality or HF hospitalization  when compared to placebo.25
• Ultrafiltration
UF is very effective at removing plasma fluid from blood across a 
semipermeable membrane that allows small molecules to pass through 
along its pressure gradient to the ultrafiltrate fluid. Small studies 
suggest that UF improves pulmonary and peripheral edema, lung 
function, and hemodynamics without adverse effects on renal function. 
The fluid removal rate is reevaluated using clinical assessment and 
serial hematocrit measurements to ensure appropriate vascular 
compartment refill. The recent development of venovenous peripheral 
UF has positioned this technique as a potential alternative to loop 
diuretics in acute HF.9
3. Conclusion
 The pathophysiology of diuretic resistance is very complex, 
and several etiologies may be involved. It derives from multiple factors, 
including reduced delivery of the diuretic to its luminal site of action, 
neurohormonal activation, tubular compensatory adaptation, and drug 
interactions6. Diuretic resistance has emerged as an independent factor 
behind worse HF patient outcomes, namely in-hospital worsening, early 
post-discharge mortality, and rehospitalizations. Once the diuretic 
resistance has been treated successfully, the treatment of advanced HF 
should be optimized in order to reduce further morbidity and mortality. 
So, it is important for clinicians to diagnose diuretic resistance in 
advanced heart failure in order to have comprehensive management.
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